The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Entecavir-associated myopathy: a case report and literature review
Yuan K, Wang G, Huang Z, Lin B, Zhou H, Lu X. Muscle Nerve. 2013 Nov 12. doi: 10.1002/mus.24118. [Epub ahead of print]
Author information
Department of Rheumatology, China-Japan Friendship Hospital, Beijing, 100029, China.
Abstract
Introduction: Entecavir, a nucleoside analogue (NA), is effective for treatment of chronic hepatitis B virus (HBV) infection. Methods: We report a patient we encountered with entecavir-associated myopathy. We also performed a literature review of myopathies associated with nucleoside analogues. Results: A 44-year-old man presented with a 3-month history of myalgia and progressive weakness. He had HBV infection and had received entecavir antiviral treatment for 5 years. Laboratory tests showed that serum creatine kinase levels were significantly elevated. Muscle histopathology showed abundant T lymphocyte infiltration of muscle fibers, and HBV surface antigen and HBV core antigen were not present inmuscle fibers. Entecavir-associated myopathy was subsequently diagnosed. His symptoms eventually resolved, and his serum CK levels decreased rapidly after he stopped receiving entecavir treatments. Conclusion: Patients who receive NA therapy should be closely monitored for myopathic side effects.